Staff Members - Benha University
A comparative study between full-dose and half-dose intravesical immune bacille Calmette–Gue´rin injection in the management of superficial bladder cancer
• 2019
Publication Information
Authors
Wael Kandeel, Ashraf Abdelal, Basheer N. Elmohamady *, Ahmed Sebaey,
Waleed Elshaaer, Ehab Elbarky, Osama Abdelwahab
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Abstract Objectives: To determine whether a half-dose of bacille Calmette–Gue´rin
(BCG) can reduce toxicity without affecting its efficacy in the management of nonmuscle-invasive bladder cancer.
Patients and methods: From January 2012 to January 2014, 80 patients with
superficial bladder cancer and in the intermediate-risk group were simply randomised to receive two different doses of BCG, i.e., a full dose of 90 mg (group
A) or a half-dose of 45 mg (group B). There were no significant differences in clinical
and pathological characteristics between the groups. At completion of the study, 40
patients could be evaluated in each group.
Results: All patients were evaluated for a follow-up of 12 months after treatment.
There was no significant difference in recurrence rate (15 patients, 38%, in group A
and 16, 40%, in group B) in the two groups, and no difference in progression rate of
the disease, at eight patients (20%) in each group. There were significant differences
(BCG) can reduce toxicity without affecting its efficacy in the management of nonmuscle-invasive bladder cancer.
Patients and methods: From January 2012 to January 2014, 80 patients with
superficial bladder cancer and in the intermediate-risk group were simply randomised to receive two different doses of BCG, i.e., a full dose of 90 mg (group
A) or a half-dose of 45 mg (group B). There were no significant differences in clinical
and pathological characteristics between the groups. At completion of the study, 40
patients could be evaluated in each group.
Results: All patients were evaluated for a follow-up of 12 months after treatment.
There was no significant difference in recurrence rate (15 patients, 38%, in group A
and 16, 40%, in group B) in the two groups, and no difference in progression rate of
the disease, at eight patients (20%) in each group. There were significant differences